Day: October 18, 2025

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of monotherapy anti-tumor activity with reductions in tumor biomarkers, tumor shrinkage, long-term stable disease, and a confirmed partial response in heavily pretreated patients Data support initiation of expansion cohorts at the two highest doses tested as monotherapy or combination for the treatment of advanced solid tumors SAN FRANCISCO, Oct. 18, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the presentation of new clinical data from...

3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUC CRB-701 continues to demonstrate a favorable safety and tolerability profile Registrational studies planned to start in mid-2026 Company to host an HNSCC KOL event during ESMO25NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presented as a poster at the 2025 European Society for Medical Oncology (ESMO25) Congress being held in Berlin, Germany. The poster titled, “Phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumors” by Perez et al will be presented tomorrow, October 19,...

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients In the 120 mg palazestrant cohort among patients with prior CDK4/6i treatment, median PFS was 9.2 months in patients with ESR1 wild-type tumors and 13.8 months in patients with ESR1 mutant tumors Combination continues to demonstrate favorable tolerability and a safety profile consistent with the known profiles of each drug Data support the ongoing Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline advanced or metastatic breast cancerSAN FRANCISCO, Oct. 18, 2025 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care endocrine therapy plus everolimus1 The giredestrant combination was well tolerated; no new safety signals were observed including no photopsia1 Overall survival data were immature, but a clear positive trend was seen in both the ITT and ESR1-mutated populations1 If approved, giredestrant plus everolimus could be the first and only oral selective oestrogen receptor degrader combination in the post-CDK inhibitor settingBasel, 18 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly...

FUKUOKA, Japan, Oct. 17, 2025 (GLOBE NEWSWIRE) — rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, announced a series of strategic corporate developments and global partnerships to expand its legal consulting and osteopathic clinic services on an international scale. Earlier this month, Company CEO Ryoji Baba was officially invited by the Embassy of Japan in Vietnam and appointed as a Board Member of United Nations-affiliated non-governmental organization (“NGO”) Koyamada International Foundation (“KIF”) and its affiliated organization, Guardian Girls International (“GGI”). KIF is an international NGO dedicated to promoting global peace, sustainable development, and improving quality of life through humanitarian, educational, and empowerment programs. Its initiatives...